RxDoctor Payments Data

Pratheesh Viswanathan, MD

Internal Medicine · Lemoyne, PANPI 1588655989

Payments from drug & device makers

$1,349in general payments, 2019–2025

Across 86 payments — averaging $15.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$446
  • Novo Nordisk$241
  • AbbVie$149
  • Shield Therapeutics Inc$83
  • Sunovion Pharmaceuticals Inc.$66
  • AstraZeneca$65
  • plus $300 from 14 others

What the payments were for

  • Food & beverage$1,348100%
  • Education$10%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,349 in reported general payments places this provider in the 80th percentile of 5,705 internal medicine providers in Pennsylvania.

See all internal medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$155,231
Medicare patients
348
Services billed
3,118

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban136$149,860
MounjaroTirzepatide85$133,768
JardianceEmpagliflozin102$132,309
OzempicSemaglutide68$99,966
Trelegy ElliptaFluticasone/Umeclidin/Vilanter51$54,144
Breo ElliptaFluticasone/Vilanterol79$48,718
XareltoRivaroxaban52$48,494
TrulicityDulaglutide31$37,102
FarxigaDapagliflozin Propanediol32$26,493
OxycontinOxycodone Hcl28$25,126
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog25$24,157
MyrbetriqMirabegron21$19,630
EntrestoSacubitril/Valsartan14$17,407
TradjentaLinagliptin12$15,561
Spiriva RespimatTiotropium Bromide11$14,491

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$14$170,871116 claims
PfizerEliquis$40$149,860136 claims
GSKTrelegy Ellipta, Breo Ellipta$446$102,863130 claims
Novo NordiskOzempic$241$99,96668 claims
Johnson & JohnsonXarelto$23$48,49452 claims
AstraZenecaFarxiga$65$26,49332 claims
Astellas Pharma US IncMyrbetriq$43$19,63021 claims
AbbVieSynthroid$149$1,92634 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 5,705 internal medicine providers in Pennsylvania.

Other internal medicine in Lemoyne

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →